Nephrotic Syndrome| A Pipeline Analysis Report 2018| Technavio
LONDON--(BUSINESS WIRE)--Jul 10, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat nephrotic syndrome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180710005824/en/
Technavio has published a new report on the drug development pipeline for nephrotic syndrome, including a detailed study of the pipeline molecules. (Photo: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Nephrotic syndrome: Market overview
The nephrotic syndrome occurs when the cluster of blood vessels in the kidney, which helps in the filtration of waste and excess water, gets damaged. This causes excessive excretion of protein through the urine and loss of fluid from the body that may lead to high blood cholesterol levels and high blood pressure. The symptoms of nephrotic syndrome include severe swelling in the eyes, feet, and ankles, foamy urine due to excess loss of protein in urine, weight gain, fatigue, and loss of appetite.
According to a senior market research analyst at Technavio, “Nephrotic syndrome is one of the most prominent kidney diseases. According to a research in 2016, 4.9 million adults in the US were diagnosed with kidney disorders, which accounts for 2% of the total.”
Nephrotic syndrome: Segmentation analysis
This pipeline analysis report segments the nephrotic syndrome market based on therapies employed (monotherapy), RoA (intravenous/subcutaneous, oral, and intravenous), therapeutic modalities (biological, small molecule, peptide, and fusion protein), drugs under development (CCR2 receptor, glucocorticoid receptor, inosine morphosphate dehydrogenase, melanocortin-2 receptor, renin, CD 80 and CD 86, endothelin-A receptor), MoA (CCR2 receptor antagonist, glucocorticoid receptor agonist, inosine morphosphate dehydrogenase inhibitor, melanocortin-2 receptor agonist, renin inhibitor, CD 80 and CD 86 inhibitors, endothelin-A receptor antagonist), geographical segmentation (US, China, and Belgium) and recruitment status (active, not recruiting, completed, recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005824/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/10/2018 12:35 PM/DISC: 07/10/2018 12:36 PM